Genenta Science S.P.A.

Genenta Science SpA is a clinical-stage biotechnology company, which engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors. Its lead product candidate, Temferon, was developed using its platform and carries an interferon-alpha payload. The company was founded by Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner on July 24, 2014 and is headquartered in Milan, Italy.

MILAN and NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Temferon™ for the treatment of glioblastoma multiforme (GBM).

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

MILAN, N.Y., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company engaged in the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, has entered into a development and manufacturing service agreement (MSA) with AGC Biologics S.p.A. to manufacture cell therapy lentivirus-based product for Genenta's ongoing clinical programs. AGC Biologics offers end-to-end global viral vector and cell therapy development, manufacturing and quality/regulatory services, supported by scientists with 30 years of knowledge and experience.

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

• Signs of intra-tumor pro-inflammatory state in patients• Temferon™ induced immune system reset in preclinical studies• Macrophage and T cell profiles in patients' tumor microenvironment echo preclinical findings

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

MILAN, Italy and NEW YORK, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), (“Genenta” or the “Company”), a clinical stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, provides business and financial results for the six months ended June 30, 2022.

Genenta Provides First Half 2022 Business Update and Financial Results

MILAN, Italy and NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, will present at several upcoming scientific and investor conferences.

Genenta to Present at Upcoming Scientific and Investor Conferences

MILAN, Italy and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, will present at several upcoming investor conferences in September and October.

Genenta to Present at Upcoming Investor Conferences

Think tank of Italian companies and entrepreneurs listed or to be listed on US capital markets Think tank of Italian companies and entrepreneurs listed or to be listed on US capital markets

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

MILAN, Italy and NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, will be presenting at several upcoming scientific congresses in May and June.

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

Extensive experience in business development with AstraZeneca and GSK Extensive experience in business development with AstraZeneca and GSK

Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

MILAN, Italy and NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, today announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the Securities and Exchange Commission ("SEC") on May 2, 2022. The annual report can be accessed on the Company's investor relations website at https://ir.genenta.com/financial-information/sec-filings as well as the SEC's website at http://www.sec.gov.

Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

No dose limiting toxicity observed in previous three dose level cohortsRepresents a 50% higher dose than highest prior levelUpdate of guidance for trial

Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme

Initial evidence of potential to modulate tumor microenvironment Initial evidence of potential to modulate tumor microenvironment

Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma

35 years industry experience including as CEO and founder of public company

Genenta Announces Nomination of Mark A. Sirgo as Chair

*** David Reardon, Luigi Naldini, Brad Loncar *** *** David Reardon, Luigi Naldini, Brad Loncar ***

Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

Data to be presented at the 2022 annual meeting of American Association for Cancer Research Data to be presented at the 2022 annual meeting of American Association for Cancer Research

Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme

MILAN, Italy and NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer (Temferon™), announced today that management will be participating in the following upcoming investor conferences:

Genenta to Participate at Upcoming Investor Conferences

MILAN, Italy and NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon™, announced today the closing of its upsized initial public offering of 2.4 million American Depositary Shares (“ADSs”) at a public offering price of $11.50 per ADS. Genenta also sold 720,114 ordinary shares reserved for subscription by its existing shareholders at a price of $11.50 per share. The gross proceeds from the offering, including ordinary shares, were approximately $36 million before deducting underwriting and advisory fees and offering expenses. The shares began trading on the Nasdaq Capital Market on December 15, 2021 under the ticker symbol “GNTA”.

Genenta Closes Its Upsized Initial Public Offering of American Depository Shares

MILAN, Italy and NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A., a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon™, announced today the pricing of its upsized initial public offering of 2.4 million American Depositary Shares, or ADSs, each representing one ordinary share, at a public offering price of $11.50 per share. Genenta also sold 720,114 ordinary shares reserved for subscription by its existing shareholders at a price of $11.50 per share. The gross proceeds from the offering, including ordinary shares, are expected to be approximately $36 million before deducting underwriting and advisory fees and offering expenses. In addition, Genenta has granted the underwriters an option for a period of 30 days from the date of the final prospectus to purchase an additional 360,000 ADSs, which, if exercised, the gross proceeds from the offering will be approximately $40 million.

News for Genenta Science S.P.A. Stock (GNTA)